09.04.25
What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression? David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observed? And Ehsan Rahimy, MD, reviews findings from a retrospective analysis seeking to understand if continuous glucose monitoring could reduce the risk of NPDR progressing to more serious conditions. Listen in to learn what he and his colleagues found.
View full description +
Editorially independent content, supported by Genentech
Subscribe
09.04.25
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDRDavid Lally, MD; and Ehsan Rahimy, MD
Editorially independent content, supported by Genentech
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
Editorially independent content, supported by Genentech
07.21.25
The State of Geographic Atrophy Around the Globe: Part 2 of 2Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD
Editorially independent content, supported by Astellas
07.21.25
The State of Geographic Atrophy Around the Globe: Part 1 of 2Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD
Editorially independent content, supported by Astellas
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
Editorially Independent Supported By Genentech and Neurotech.
07.07.25
GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing TherapyJudy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD
Editorially independent content, supported by Apellis
07.07.25
GA in 2025: Dosing Regimens, Drug Selection, and Ideal CandidatesJudy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD
Editorially independent content, supported by Apellis
Show More